Phase 3 study on combinational therapy of SMP-508 with pioglitazone in patients with type 2 diabetes mellitus.

Trial Profile

Phase 3 study on combinational therapy of SMP-508 with pioglitazone in patients with type 2 diabetes mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Repaglinide (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 28 Feb 2013 The Japanese regulatory authorities approved the use of repaglinide in combination with thiazolidinediones as a treatment for type 2 diabetic patients based on results from this trial according to a Dainippon Sumitomo Pharma media release.
    • 17 Apr 2012 Primary endpoint has been met, according to a Dainippon Sumitomo Pharma media release.
    • 17 Apr 2012 Status changed from recruiting to completed, according to a Dainippon Sumitomo Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top